SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRtw Biotech Regulatory News (RTW)

Share Price Information for Rtw Biotech (RTW)

Share Price is delayed by 15 minutes
Get Live Data
2.21    0.00 (0.00%)
Bid:
2.19
Ask:
2.21
Spread: 0.02 (0.913%)
Market Cap: $714.60m
RTW Live PriceLast checked at - London Stock Exchange

Intraday Rtw Biotech Share Chart

Net Asset Value(s)

14 Nov 2022 07:00

RNS Number : 1607G
RTW Venture Fund Limited
14 November 2022
 

LEI: 549300Q7EXQQH6KF7Z84

14 November 2022

RTW Venture Fund Limited

Net Asset Value

RTW Venture Fund Limited (the "Company") announces that the unaudited net asset value attributable to the ordinary shares of the Company at the close of business on 31 October 2022 (the "NAV") was US$307 million, or US$1.45 per ordinary share, an increase of 0.6% from the previous month.

As at 31 October 2022, 26.9% of the total NAV was invested in privately-held core portfolio companies and 40.8% of the total NAV was invested in public core portfolio companies, most of which were initiated as private investments. 28.9% was invested in other liquid public positions (which mirror holdings in RTW Investments, LP private funds) in lieu of holding cash for future core investments.

For Further Information:

RTW Investments, LP

+44 (0) 77 1741 7711

Woody Stileman, Managing Director

 

 

 

Buchanan

+44 (0)20 7466 5107

Charles Ryland

 

Henry Wilson

 

George Beale

 

 

 

J.P. Morgan Cazenove

+44 (0)20 7742 4000

William Simmonds

 

Jérémie Birnbaum

 

James Bouverat (Sales)

 

 

BofA Securities

+44 (0) 20 7628 1000

Edward Peel

 

Kieran Millar

 

 

Elysium Fund Management Limited

+44 (0) 14 8181 0100

Joanna Duquemin Nicolle, Chief Executive Officer

 

Sadie Morrison, Managing Director

 

 

 

Morgan Stanley Fund Services USA LLC

+1 (914) 225 8885

 

 

Note:

1.

The NAV is determined by the Company's investment manager, RTW Investments, LP, in accordance with the Company's accounting policies. Investments by the Company in privately-held companies ("Private Portfolio Companies") have been valued at fair market value, taking into account the valuation prepared by Alvarez & Marsal Valuation Services LLC and the nature, facts and circumstances of the Private Portfolio Companies. Investments by the Company in companies listed on a public stock exchange (the "Public Portfolio Companies") have each been valued by reference to their market capitalisation as at close of business on 31 October 2022. The Company applies a valuation discount to its investments in Public Portfolio Companies that are subject to post-IPO lock-up provisions.

About RTW Venture Fund Limited:

RTW Venture Fund Limited (LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.

RTW Venture Fund Limited is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the RTW website at www.rtwfunds.com for more information.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NAVGPGAAGUPPGUG
Date   Source Headline
8th Feb 20217:00 amRNSPortfolio Company Update: Immunocore IPO
5th Feb 20217:00 amRNSPortfolio Company Update: Landos IPO
1st Feb 20217:00 amRNSChange of Administrator and Company Secretary
1st Feb 20217:00 amRNSTotal Voting Rights
25th Jan 202110:04 amRNSDirector/PDMR Shareholding
22nd Jan 20217:00 amRNSQuarterly Update
19th Jan 20216:11 pmRNSIssue of Equity
15th Jan 20213:39 pmRNSAnnouncement of Share Issuance
15th Jan 20217:00 amRNSNet Asset Value
11th Jan 202112:22 pmRNSAdditional Investment in Portfolio Company
6th Jan 20213:30 pmRNSNew Investment in Biomea Fusion
29th Dec 202010:16 amRNSDirector/PDMR Shareholding
24th Dec 20208:35 amRNSDirector/PDMR Shareholding
23rd Dec 20209:07 amRNSDirector/PDMR Shareholding
14th Dec 20207:00 amRNSNet Asset Value(s)
10th Dec 20207:00 amRNSTransformational Update from Largest Holding
8th Dec 20208:03 amRNSNew Investment in Nuance Pharma
1st Dec 20207:00 amRNSTotal Voting Rights
16th Nov 20205:59 pmRNSIssue of Equity
13th Nov 20206:22 pmRNSAnnouncement of Share Issuance
13th Nov 20207:00 amRNSNet Asset Value(s)
10th Nov 20209:26 amRNSHolding(s) in Company
9th Nov 20202:00 pmRNSNew Investment in Prometheus Biosciences
2nd Nov 20207:00 amRNSTotal Voting Rights
28th Oct 20201:25 pmRNSHolding(s) in Company
19th Oct 20207:01 amRNSTarsus Pharmaceuticals Prices $88 Million IPO
19th Oct 20207:00 amRNSQuarterly Update
16th Oct 20205:19 pmRNSIssue of Equity
14th Oct 20202:31 pmRNSAnnouncement of Share Issuance
14th Oct 20207:00 amRNSNet Asset Value(s)
5th Oct 20207:00 amRNSC4 Therapeutics Prices $182 Million IPO
2nd Oct 20207:00 amRNSPulmonx Prices $190 Million IPO
28th Sep 20204:13 pmRNSHolding(s) in Company
24th Sep 20207:00 amRNSInterim Report for the period ended 30 June 2020
21st Sep 20207:00 amRNSAthira Pharma Prices $204.0 Million IPO
15th Sep 20207:00 amRNSNet Asset Value(s)
14th Sep 20201:00 pmRNSSeries B Financing Round in NiKang Therapeutics
2nd Sep 20207:00 amRNSNotice of Interim Report
1st Sep 20207:00 amRNSTotal Voting Rights
17th Aug 20205:16 pmRNSIssue of Equity
14th Aug 20202:01 pmRNSAnnouncement of Share Issuance
14th Aug 20207:00 amRNSNet Asset Value(s)
12th Aug 20207:00 amRNSPortfolio Company Update
3rd Aug 20207:00 amRNSTotal Voting Rights
28th Jul 20206:25 pmRNSHolding(s) in Company
27th Jul 20207:00 amRNSiTeos Therapeutics Prices $201 Million IPO
23rd Jul 202012:00 pmRNSNew Investment in Milestone Pharmaceuticals
22nd Jul 20201:00 pmRNSSeries D Financing in Encoded Therapeutics
21st Jul 20207:00 amRNSQuarterly Update
17th Jul 202011:44 amRNSIssue of Equity - Replacement Announcement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.